Regional hyperthermia of the abdomen in conjunction with chemotherapy for peritoneal carcinomatosis: Evaluation of two annular-phased-array applicators

References

• Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995; 221: 124–132
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, Zoetmulder FAN. Randomized trial of cytoreduction and hyperthermic introperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737–3743
   PubMed Web of Science ®Google Scholar
• De Bree E, Witkamp AJ, Zoetmulder FAN. Intraperitoneal chemotherapy for colorectal cancer. J Surg Oncol 2002; 79: 46–61
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Engl J Med 2006; 354: 34–43
   PubMed Web of Science ®Google Scholar
• Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, Felix R, Schlag PM. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002; 3: 487–497
   PubMed Web of Science ®Google Scholar
• Jones E, Secord AA, Prosnitz LR, Samulski TV, Oleson JR, Berchuck A, Clarke-Pearson D, Soper J, Dewhirst MW, Vujaskovic Z. Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma. Int J Hyperthermia 2006; 22: 161–172
   PubMed Web of Science ®Google Scholar
• Hildebrandt B, Rau B, Gellermann J, Wust P, Riess H. Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinosis. J Clin Oncol 2004; 22(8)1527–1529
   PubMedGoogle Scholar
• Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R, Riess H. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002; 43: 33–56
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Vujaskovic Z, JNones E, Thrall D. Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 2005; 21: 779–790
   PubMed Web of Science ®Google Scholar
• Gellermann J, Wlodarczyk W, Ganter H, et al. A practical approach to perform the thermography in a hyperthermia/MR hybrid system - validation in an anthropomorphous phantom. Int J Radiat Oncol Biol Phys 2005; 61: 267–277
   PubMed Web of Science ®Google Scholar
• Wust P, Cho CH, Hildebrandt B, Gellermann J. Thermal monitoring: Invasive, minimal-invasive and non-invasive approaches. Int J Hyperthermia 2006; 22: 255–262
   PubMed Web of Science ®Google Scholar
• Sadeghi B, Arvieux C, Glehen O, Beaujard A, Rivoire M, Beaulieux J, et al. Peritoneal carcinomatosis from non-gynecological malignancies. Results of the EVOCAPE 1 multi-centric prospective study. Cancer 2000; 88: 58–63
   PubMedGoogle Scholar
• Chu DZJ, Lang NP, Thomson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989; 63: 374–377
   Google Scholar
• Fujimura T, Yonemura Y, Fujita H, Michiwa Y, Kawamura T, Nojima N, et al. Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intraabdominal malignancies. Int Surg 1999; 84: 60–66
   PubMed Web of Science ®Google Scholar
• Witkamp AJ, de Bree E, Kaag MM, Boot H, Beijnen JH, van Slooten GW, et al. Extensive cytoreductive surgery followed by intraoperative hyperthermic intraperitoneal chemotherapy with mitomycin C for colorectal cancer with peritoneal metastases. Eur J Cancer 2001; 37: 979–984
   PubMed Web of Science ®Google Scholar
• Elias D, Blot F, El Otmani A, Antoun S, Lasser P, Boige V, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 92: 71–76
   PubMed Web of Science ®Google Scholar
• Gertsch P. A historical perspective on colorectal liver metases and peritoneal carcinomatosis: Similar results, different treatments. Surg Oncol Clin N Am 2003; 12: 531–541
   PubMedGoogle Scholar
• Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, et al. Paclitaxel for platinum refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Referral center 9103. J Clin Oncol 1993; 11: 2405–2410
   PubMed Web of Science ®Google Scholar
• González-Martin A. Treatment of recurrent disease: Randomized trials of monotherapy versus combination chemotherapy. Int J Gynecol Cancer 2005; 15(Suppl. 3)241–246
   PubMedGoogle Scholar
• Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Benedetti-Panici P, Bonetti A, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A ranzomized phase II study of the European Organization for Res. and Treatment of Cancer Gynecology Group. J Clin Oncol 2000; 18: 1193–1202
   PubMed Web of Science ®Google Scholar
• Gordon AN, Tonda M, Sun S, Rachoff W. 2004; 95: 1–8, on behalf of the Doxil Study 30–49 investigators. Gyn Oncol
   Google Scholar
• Sreenivasa G, Gellermann J, Rau R, et al. Clinical application of the hyperthermia treatment planning system HyperPlan - comparison of algorithms and clinical observables. Int J Radiat Oncol Biol Phys 2003; 55: 407–419
   PubMed Web of Science ®Google Scholar
• Gellermann J, Weihrauch M, Cho CH, et al. Comparison of MR-thermography and planning calculations in phantoms. Med Phys 2006; 33: 3912–3920
   PubMed Web of Science ®Google Scholar
• Weihrauch M, Wust P, Weiser M, et al. Adaptation of antenna profiles for control of MR guided hyperthermia (HAT) in a hybrid system. Med Phys 2007; 34: 4717–4725
   PubMed Web of Science ®Google Scholar